#	Pagina
attuale pagina	/open-h2020/projects/224621/index.html

Opendata, web and dolomites

QTB4AMR SIGNED

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Total Cost €

EC-Contrib. €

Partnership

Views

QTB4AMR project word cloud

Explore the words cloud of the QTB4AMR project. It provides you a very rough idea of what is the project "QTB4AMR" about.

exhibit gentamicin standard resistant efforts conceptually restore painstaking care forth resistance compounds gram tackle posed displayed decades gmpcides attractive emergence antibiotic arbs billions amr circumventing companies protect antibiotics vancomycin sensitize pathogens synergy chemical scalable drug proposition confront yield world effectiveness euros mrsa pharmaceutical fast antimicrobial pathogen discovering positive breakers bacteria worth vre threatening vivo platform

Project "QTB4AMR" data sheet

The following table provides information about the project.

Coordinator	QURETECH BIO AB Organization address address: TVISTEVAGEN 48C city: UMEA postcode: 907 36 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-08-01 to 2020-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	QURETECH BIO AB QURETECH BIO AB Organization address address: TVISTEVAGEN 48C city: UMEA postcode: 907 36 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UMEA)	coordinator	50˙000.00

Map

Project objective

We tackle the challenges posed by the emergence of antimicrobial resistance (AMR) with a conceptually new approach. We have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). Our compounds sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. By circumventing the painstaking process of discovering and developing new antibiotics, we bring forth a more cost-effective approach to confront the emergence of AMR. Allowing pharmaceutical companies to protect decades worth of R&D efforts and billions of euros in development costs, we present them with an attractive value proposition. Our platform enables the fast, high-yield production of ARBs against gram-positive bacteria (GmPcides). Our compounds have displayed effectiveness against two of the most threatening drug-resistant pathogens MRSA and VRE. Moreover, the compounds exhibit a strong in vivo synergy with two of the world’s most essential antibiotics Gentamicin and Vancomycin.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QTB4AMR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QTB4AMR" are provided by the European Opendata Portal: CORDIS opendata.